<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397458</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-20-0124</org_study_id>
    <nct_id>NCT04397458</nct_id>
  </id_info>
  <brief_title>Rescue Quadratus Lumborum Blocks for Post-cesarean Pain</brief_title>
  <official_title>Rescue Quadratus Lumborum Blocks for Post-cesarean Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether quadratus lumborum (QL) block performed 1 day&#xD;
      after cesarean delivery will provide supplemental post-cesarean analgesia and reduce opioid&#xD;
      requirements.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total opioid consumption</measure>
    <time_frame>48 hours after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of opioids used</measure>
    <time_frame>at the time of intervention (one day following cesarean delivery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of opioids used</measure>
    <time_frame>6 hours after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of opioids used</measure>
    <time_frame>12 hours after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of opioids used</measure>
    <time_frame>24 hours after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of opioids used</measure>
    <time_frame>48 hours after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from quadratus lumborum block until first opioid request</measure>
    <time_frame>from time of intervention until time of first opioid request (up to 48 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as measured by an 11-point verbal pain score (at rest)</measure>
    <time_frame>at the time of intervention (one day following cesarean delivery)</time_frame>
    <description>The 11-point verbal pain score ranges from 0-10, with a higher number indicating worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as measured by an 11-point verbal pain score (with movement)</measure>
    <time_frame>at the time of intervention (one day following cesarean delivery)</time_frame>
    <description>The 11-point verbal pain score ranges from 0-10, with a higher number indicating worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as measured by an 11-point verbal pain score (at rest)</measure>
    <time_frame>6 hours after intervention</time_frame>
    <description>The 11-point verbal pain score ranges from 0-10, with a higher number indicating worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as measured by an 11-point verbal pain score (with movement)</measure>
    <time_frame>6 hours after intervention</time_frame>
    <description>The 11-point verbal pain score ranges from 0-10, with a higher number indicating worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as measured by an 11-point verbal pain score (at rest)</measure>
    <time_frame>12 hours after intervention</time_frame>
    <description>The 11-point verbal pain score ranges from 0-10, with a higher number indicating worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as measured by an 11-point verbal pain score (with movement)</measure>
    <time_frame>12 hours after intervention</time_frame>
    <description>The 11-point verbal pain score ranges from 0-10, with a higher number indicating worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as measured by an 11-point verbal pain score (at rest)</measure>
    <time_frame>24 hours after intervention</time_frame>
    <description>The 11-point verbal pain score ranges from 0-10, with a higher number indicating worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as measured by an 11-point verbal pain score (with movement)</measure>
    <time_frame>24 hours after intervention</time_frame>
    <description>The 11-point verbal pain score ranges from 0-10, with a higher number indicating worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as measured by an 11-point verbal pain score (at rest)</measure>
    <time_frame>48 hours after intervention</time_frame>
    <description>The 11-point verbal pain score ranges from 0-10, with a higher number indicating worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as measured by an 11-point verbal pain score (with movement)</measure>
    <time_frame>48 hours after intervention</time_frame>
    <description>The 11-point verbal pain score ranges from 0-10, with a higher number indicating worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea as measured by a 3-point scale</measure>
    <time_frame>at the time of intervention (one day following cesarean delivery)</time_frame>
    <description>This is measured categorically as none, mild, or moderate-severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea as measured by a 3-point scale</measure>
    <time_frame>6 hours after intervention</time_frame>
    <description>This is measured categorically as none, mild, or moderate-severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea as measured by a 3-point scale</measure>
    <time_frame>12 hours after intervention</time_frame>
    <description>This is measured categorically as none, mild, or moderate-severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea, pruritus and sedation as measured by a 3-point scale</measure>
    <time_frame>24 hours after intervention</time_frame>
    <description>This is measured categorically as none, mild, or moderate-severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea as measured by a 3-point scale</measure>
    <time_frame>48 hours after intervention</time_frame>
    <description>This is measured categorically as none, mild, or moderate-severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus as measured by a 3-point scale</measure>
    <time_frame>at the time of intervention (one day following cesarean delivery)</time_frame>
    <description>This is measured categorically as none, mild, or moderate-severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus as measured by a 3-point scale</measure>
    <time_frame>6 hours after intervention</time_frame>
    <description>This is measured categorically as none, mild, or moderate-severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus as measured by a 3-point scale</measure>
    <time_frame>12 hours after intervention</time_frame>
    <description>This is measured categorically as none, mild, or moderate-severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus as measured by a 3-point scale</measure>
    <time_frame>24 hours after intervention</time_frame>
    <description>This is measured categorically as none, mild, or moderate-severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus as measured by a 3-point scale</measure>
    <time_frame>48 hours after intervention</time_frame>
    <description>This is measured categorically as none, mild, or moderate-severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation as measured by a 3-point scale</measure>
    <time_frame>at the time of intervention (one day following cesarean delivery)</time_frame>
    <description>This is measured categorically as none, mild, or moderate-severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation as measured by a 3-point scale</measure>
    <time_frame>6 hours after intervention</time_frame>
    <description>This is measured categorically as none, mild, or moderate-severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation as measured by a 3-point scale</measure>
    <time_frame>12 hours after intervention</time_frame>
    <description>This is measured categorically as none, mild, or moderate-severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation as measured by a 3-point scale</measure>
    <time_frame>24 hours after intervention</time_frame>
    <description>This is measured categorically as none, mild, or moderate-severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation as measured by a 3-point scale</measure>
    <time_frame>48 hours after intervention</time_frame>
    <description>This is measured categorically as none, mild, or moderate-severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction as measured by the 5-point Likert scale</measure>
    <time_frame>48 hours after intervention</time_frame>
    <description>The 5-point scale ranges from extremely satisfied to not satisfied.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Morphine</condition>
  <condition>Analgesics</condition>
  <condition>Analgesics, Opioid</condition>
  <condition>Peripheral Nervous System Agents</condition>
  <arm_group>
    <arm_group_label>Sham Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>20 milliliters (mL) 0.9% saline on each side</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadratus Lumborum Block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mL solution with 0.25% bupivacaine (50 milligrams (mg)) and 3mg preservative-free dexamethasone on each side</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>0.9% saline on each side</description>
    <arm_group_label>Sham Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>0.25% bupivacaine (50mg) on each side</description>
    <arm_group_label>Quadratus Lumborum Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>3mg preservative-free dexamethasone on each side</description>
    <arm_group_label>Quadratus Lumborum Block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  elective or non-elective cesarean delivery on prior day&#xD;
&#xD;
          -  pain scores &gt;5/10&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt;40&#xD;
&#xD;
          -  obstructive sleep apnea&#xD;
&#xD;
          -  drug abuse&#xD;
&#xD;
          -  chronic pain&#xD;
&#xD;
          -  chronic opioid use&#xD;
&#xD;
          -  abdominal surgeries other than cesarean delivery&#xD;
&#xD;
          -  contraindications to neuraxial or regional anesthesia&#xD;
&#xD;
          -  received general anesthesia or did not receive neuraxial morphine for cesarean&#xD;
             delivery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linden Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linden Lee, MD</last_name>
    <phone>(713) 500-6200</phone>
    <email>Linden.O.Lee@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Lisa Ramirez-Chapman</last_name>
    <phone>(713) 566-5971</phone>
    <email>Ana.L.RamirezChapman@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Linden Lee, MD</last_name>
      <phone>713-500-6200</phone>
      <email>Linden.O.Lee@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ana Lisa Ramirez-Chapman</last_name>
      <phone>(713) 566-5971</phone>
      <email>Ana.L.RamirezChapman@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Linden Lee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>quadratus lumborum block</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>cesarean delivery</keyword>
  <keyword>c-section</keyword>
  <keyword>intrathecal morphine</keyword>
  <keyword>post-operative pain</keyword>
  <keyword>post-cesarean analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

